12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Company News  |  Other News

Eli Lilly pharmaceuticals news

Eli Lilly plans to restructure its U.S. sales force due to the "changing customer realities, evolutions in the health care environment and upcoming loss of exclusivity" for neurology drug Cymbalta duloxetine and osteoporosis and cancer drug Evista raloxifene. Lilly said the sales force for neuroscience, musculoskeletal, cardiovascular and men's health will "move to a smaller...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >